Merit Medical Raises 2026 EPS Guidance and Acquires Solo Pace for ~$45M, Deepening Cardiac Therapies Platform

Event Analysis

Merit Medical Systems (MMSI) announced two related developments on October 29, 2026: an upward revision to its 2026 non-GAAP diluted EPS outlook and completion of the Solo Pace acquisition. According to GlobeNewswire, Merit acquired all remaining outstanding equity of Solo Pace, Inc. on October 13, 2026, for approximately $45 million in cash — having previously held an 18% stake and served as its exclusive distributor. The new 2026 non-GAAP EPS range of $4.33–$4.37 (midpoint $4.35) is up from a prior range of $4.25–$4.35 (midpoint $4.30), representing roughly a 1.2% upward midpoint revision and implied growth of approximately 13%–14% year over year.

The Solo Pace deal adds the Solo Pace Control and Solo Pace Fusion products — temporary cardiac pacing systems designed specifically for TAVR (transcatheter aortic valve replacement) and related transcatheter heart-valve procedures — to Merit's Cardiac Therapies platform. This is a classic vertical tuck-in: Merit already distributed these products and held a minority equity stake, so the acquisition is less about entering new territory and more about internalizing economics and commercial control over a strategically relevant product line. This type of deal, well-explored in the broader M&A acquisition wave playing out across medical devices, signals management confidence in the structural-heart catheter market's long-term growth.

As reported by TipRanks, the guidance raise followed a strong Q3 in which revenue reached approximately $416.2 million (up 8.4% year over year) and non-GAAP EPS grew 22% to $1.12. The Solo Pace deal is expected to be immaterial to 2026 financials given its October close, but slightly accretive to 2027 non-GAAP EPS — offset by approximately $1.5 million of lower interest income from cash deployment and $3.2 million in non-cash/non-recurring transaction expenses.

What distinguishes this event from a standard tuck-in is the pre-existing commercial relationship. Merit was not acquiring a cold asset — it was converting distribution rights and a minority stake into full ownership, reducing supplier dependency and capturing margin that previously flowed outward. For the structural-heart device ecosystem, it reinforces that companies with TAVR-adjacent pacing and delivery technologies remain attractive consolidation targets.

What This Means for Traders

The primary price-sensitive element for MMSI is the EPS guidance upgrade, not the acquisition. A ~1.2% midpoint revision following a 22% non-GAAP EPS beat in Q3 signals operating momentum, but the magnitude of the guidance lift is modest. Investors who anticipated strong Q3 performance may already have priced in improvement, limiting near-term upside surprise potential. The sector acquisition playbook for tuck-in medtech deals generally shows limited stock re-rating unless the acquired asset is transformational — this one is not, by management's own characterization.

For traders watching the broader medtech and structural-heart space, the deal reinforces a theme of energy, pharma, and tech M&A where incumbents are locking in niche procedural technologies ahead of anticipated TAVR volume growth. Companies exposed to catheter-based cardiac procedures, electrophysiology, and pacing could see incremental sentiment support. MMSI as a CFD on CoinUnited would fall under standard stock trading hours — traders should monitor the next session open for price action confirmation following this after-hours announcement.

Volatility for MMSI specifically is likely to be contained. The acquisition is small relative to Merit's revenue base, 2026 impact is immaterial by management's own guidance, and the EPS revision — while directionally positive — is incremental rather than material. Sentiment is mildly bullish for MMSI; neutral-to-slightly-positive for medtech peers with TAVR exposure.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices and commodities from one crypto-funded account. Leverage up to 2000x on selected products, subject to eligibility; fees are tiered by 30-day volume.